Serotonin norepinephrine reuptake inhibitors:A pharmacological comparison

Innovations in Clinical Neuroscience

Volumn 11, Issue 3-4, 2014, Pages 37-42

  Sansone, Randy A ^a   Sansone, Lori A ^b  

^a WRIGHT STATE UNIVERSITY   (United States)

^b WRIGHT PATTERSON AIR FORCE BASE   (United States)

Author keywords

Antidepressants; Desvenlafaxine; Duloxetine; Levomilnacipran; Milnacipran; Selective serotonin reuptake inhibitors; SNRIs; Venlafaxine

Indexed keywords

CYTOCHROME P450 1A2; CYTOCHROME P450 2D6; CYTOCHROME P450 3A; DESVENLAFAXINE; DULOXETINE; MILNACIPRAN; NORADRENALIN; PRISTIQUE; SEROTONIN; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; UNCLASSIFIED DRUG; VENLAFAXINE;

ARTICLE; DRUG HALF LIFE; DRUG METABOLISM; FIBROMYALGIA; FOOD AND DRUG ADMINISTRATION; GENERALIZED ANXIETY DISORDER; GENETIC POLYMORPHISM; HUMAN; MAJOR DEPRESSION; MUSCULOSKELETAL PAIN; OSTEOARTHRITIS; PANIC; SOCIAL PHOBIA;

EID: 84900004075     PISSN: 21588333     EISSN: 21588341     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Gold Standard, Inc. Venlafaxine. Clinical Pharmacology [database online]. http://www.clinicalpharmacology.com. Accessed on 7/9/13.
2. Olver JS, Burrows GD, Norman TR. The treatment of depression with different formulations of venlafaxine: a comparative analysis. Hum Psychopharmacol. 2004;19:9-16.
3. Montgomery SA. Tolerability of serotonin norepinephrine reuptake inhibitor antidepressants. CNS Spectr. 2008;13:27-33.
4. nd ed. Baltimore: Lippincott, Williams & Wilkins; 1997.
5. Gold Standard, Inc. Duloxetine. Clinical Pharmacology [database online].http://www.clinicalpharmacology.com. Accessed on 7/9/13.
6. Kuo F, Gillespie TA, Kulanthaivel P, et al. Synthesis and biological activity of some known and putative duloxetine metabolites. Bioorg Med Chem Lett. 2004;14:3481-3486.
7. Hunziker ME, Suehs BT, Bettinger TL, Crismon ML. Duloxetine hydrochloride: a new dual-acting medication for the treatment of major depressive disorder. Clin Ther. 2005;27:1126-1143.
8. Stahl SM, Grady MM, Moret C, Briley M. SNRIs: their pharmacology, clinical efficacy, and tolerability in comparison with other classes of antidepressants. CNS Spectr. 2005;10:732-747.
9. Turcotte JE, Debonnel G, de Montigny C, et al. Assessment of the serotonin and norepinephrine reuptake blocking properties of duloxetine in healthy subjects. Neuropsychopharmacology. 2001;24:511-521.
10. Gold Standard, Inc. Desvenlafaxine. Clinical Pharmacology [database online].http://www.clinicalpharmacology.com. Accessed on 7/9/13.
11. Perry R, Cassagnol M. Desvenlafaxine: a new serotoninnorepinephrine reuptake inhibitor for the treatment of adults with major depressive disorder. Clin Ther. 2009;31:1374-1404.
12. Desvenlafaxine Package Insert. http://labeling.pfizer.com/showlabeling.aspx?id=497. Accessed on 7/15/13.
13. Lourenco MT, Kennedy SH. Desvenlafaxine in the treatment of major depressive disorder. Neuropsychiatr Dis Treat. 2009;5:127-136.
14. Cohen LJ. Desvenlafaxine: frequently asked questions. Prim Psychiatry. 2009;16:1-8.
15. Seo HJ, Sohi MS, Patkar AA, et al. Desvenlafaxine succinate: a newer antidepressant for the treatment of depression and somatic symptoms. Postgrad Med. 2010;122:125-138.
16. Deecher DC, Beyer CE, Johnston G, et al. Desvenlafaxine succinate: a new serotonin and norepinephrine reuptake inhibitor. J Pharmacol Exp Ther. 2006;318:657-665.
17. Kasper S, Pail G. Milnacipran: a unique antidepressant? Neuropsychiatr Dis Treat. 2010;6:S23-31.
18. Gold Standard, Inc. Milnacipran. Clinical Pharmacology [database online].http://www.clinicalpharmacology.com. Accessed on 7/9/13.
19. Delini-Stula A. Milnacipran: an antidepressant with dual selectivity of action on noradrenaline and serotonin reuptake. Hum Psychopharmacol. 2000;15:255-260.
20. Auclair AL, Martel JC, Assie MB, et al. Levomilnacipran (F2695), a norepinephrine-preferring SNRI: profile in vitro and in models of depression and anxiety. Neuropharmacology. 2013;70:338-347.
21. Clinical Trials.Gov. Safety and efficacy of levomilnacipran SR in major depressive disorder. http://clinicaltrials.gov/ct2/show/NCT01377194. Accessed on 7/17/13.
22. Forest Pharmaceuticals, Inc. Highlights of prescribing information. https://www.fetzima.com/?guid=google577. Accessed on 7/31/13.